Pharmaceutical Business Products | Otsuka Pharmaceutical Co., Ltd.

It is a link for moving within the page.

  1. HOME
  2. Pharmaceutical Business
  3. Pharmaceutical Business Products

Pharmaceutical Business Products

By choosing to tackle unaddressed medical needs, we put ourselves on the path to creating new therapeutic approaches and unprecedented drugs. Our researchers are committed to continuing to take the road less travelled, to develop solutions that only we can create.

Otsuka prescription drugs on the global market

Central Nervous System

Oncology

Cardiovascular and Renal areas

Gastrointestinal

Infectious diseases

Ophthalmology

Diagnostics

This page introduces medical product information related to Otsuka Pharmaceutical's business.
However, it is not intended to indicate or promote the use of these products.

For a better understanding of how to use our drugs correctly

Antipsychotic

REXULTI (sold in the U.S. and several other countries)

REXULTI was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder. REXULTI acts as an SDAM(serotonin-dopamine activity modulator).

The information in the product description is current as of November 2017.

Antipsychotic

ABILIFY Maintena, a prolonged release aquaeous suspension for intramuscular injection

Abilify Maintena is administered once every four weeks. It is a formulation of the antipsychotic ABILIFY, which has a dopamine D2 receptor partial agonist action. In 2013, it was first launched in the U.S. with an indication for schizophrenia and subsequently has become available in multiple countries. In 2017 the product was approved for use in treatment of bipolar I disorder in the U.S. and Canada.

The information in the product description is current as of November 2017.

Antipsychotic

ABILIFY

ABILIIFY is an antipsychotic with the world's first dopamine D2 receptor partial agonist action, which was discovered by Otsuka. In Japan it was launched in 2006 for the treatment of schizophrenia and in 2012 obtained an additional indication for improvement of manic symptoms of bipolar disorder. Following its launch in the U.S. in 2002, ABILIFY has been approved in more than 60 countries worldwide.

The information in the product description is current as of November 2017.

Pseudobulbar Affect (PBA) agent

NUEDEXTA (sold in the U.S.)

NUEDEXTA is the world's first and only approved treatment for pseudobulbar affect (PBA). It is a combination of dextromethorphan hydrobromide, which acts on the central nervous system, and quinidine sulfate, which inhibits metabolism in order to increase the effective blood concentration of dextromethorphan. It is marketed by Avanir Pharmaceuticals, an affiliate in the U.S.

The information in the product description is current as of November 2017.

Antiepileptic

E Keppra

E Keppra, an antiepileptic originally developed by the Belgian company UCB, has a novel mechanism of action that binds to synaptic vesicle proteins in the brain. Since being approved in the U.S. in 1999 the drug has been sold by UCB in multiple countries. In Japan, Otsuka has co-marketed E Keppra with UCB Japan since 2010.

The information in the product description is current as of November 2017.

Dopaminergic antiparkinsonian agent
Restless legs syndrome agent

Neupro Patch

Neupro Patch is the world's only once-daily transdermal dopamine agonist. Otsuka obtained development and marketing rights in Japan from the Belgian company UCB. In Japan, it has been marketed since 2013.

The information in the product description is current as of November 2017.

Acute treatment of migraine

ONZETRA Xsail (sold in the U.S.)

Marketed by US affiliate Avanir Pharmaceuticals, ONZETRA is a rapidly absorbed sumatriptan nasal powder formulation delivered to the back of the nose. ONZETRA was launched in the U.S. in 2016.

The information in the product description is current as of November 2017.

<Oncology>
Anti-leukemia agent

ICLUSIG

ICLUSIG, discovered by Ariad, an oral tyrosine kinase inhibitor, targets BCR-ABL, an abnormal kinase expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ICLUSIG was launched in Japan in 2016.

The information in the product description is current as of November 2017.

Conditioning agent prior to allogenic hematopoietic progenitor cell transplantation

Busulfex

Busulfex, the only drug approved by the U.S. Food and Drug Administration, is a conditioning agent prior to bone marrow transplantation in blood cancer. It has been accepted globally as a standard treatment to support medical transplantation.

The information in the product description is current as of November 2017.

DNA methylation inhibitor

Dacogen

Dacogen is a therapeutic agent for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It has been sold by US-affiliate Astex since 2008.

The information in the product description is current as of November 2017.

<Cardiovascular and Renal areas>
V2-receptor antagonist
Aquaretic and ADPKD treatment drug

Samsca / JINARC*

brand name outside Japan for ADPKD indication

Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affecting the excretion of electrolytes. It does this by inhibiting the antidiuretic hormone vasopressin. In Japan, it was approved for edema from heart failure (accumulation of fluid) in 2010 and edema for cirrhotic patients in 2013. In 2014 Samsca was approved in Japan as the first-in-the-world treatment of autosomal dominant polycystic kidney disease (ADPKD), and additional approvals have been received in multiple countries. Currently, Samsca/JINARC is approved for sale in over 40 countries.

The information in the product description is current as of November 2017.

Antiplatelet agent

Pletaal

Pletaal, discovered by Otsuka, inhibits platelet aggregation and has peripheral vasodilator effects. In Japan it was launched in 1988 for the treatment of symptoms associated with chronic arterial obstruction and was also approved in 2003 for prevention of recurrent cerebral infarction. In 2010, Pletaal OD tablets were released in Japan.

The information in the product description is current as of November 2017.

<Gastrointestinal>
Anti-gastritis and anti-gastric ulcer agent

Mucosta

Otsuka-discovered Mucosta has an action that protects the gastric mucosa in addition to suppressing free radicals and inflammation in the stomach. It is widely used as a drug to control gastric mucosa injury triggered by various causes such as use of painkillers and the effects of Helicobacter pylori. It was launched in Japan in 1990 and is now sold in multiple countries.

The information in the product description is current as of November 2017.

Anti-MDR (multidrug-resistant) tuberculosis drug

DELTYBA

DELTYBA, discovered by Otsuka, is one of the first new anti-tuberculosis (TB) agents in nearly 50 years. It has a new mechanism of action with antimicrobial effect by inhibition of the production of mycolic acids, which form the cell wall of TB bacteria. As a treatment for multidrug-resistant TB, DELTYBA was approved in Europe in 2014. In Japan, it was also launched in 2014. In 2015 it was listed in the WHO Essential Medicines List.

The information in the product description is current as of November 2017.

<Ophthalmology>
Therapeutic agent for dry eye

Mucosta ophthalmic suspension

Mucosta ophthalmic suspension is a novel dry eye treatment with action that repairs corneal and conjunctival damage by promoting the production of mucin. It was launched in Japan in 2012 as a disposable, unit-dose formulation.

The information in the product description is current as of November 2017.

Antiglaucoma and anti-intraocular hypertension drug

Mikeluna combination ophthalmic solution

Mikeluna combination ophthalmic solution is an once-daily eye drop containing a combination of the Otsuka-developed β-blocker cartelol hydrochloride (Mikelan LA) and the prostaglandin analogue latanoprost. It launched in Japan in 2017.

The information in the product description is current as of November 2017.

13C-Urea breath agent for diagnosis of H. pylori infection

UBIT tablet

UBIT, discovered by Otsuka, is a diagnostic agent that measures 13C-Urea in the breath to detect the presence of Helicobacter pylori in the stomach.

The information in the product description is current as of November 2017.